[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2019194217A1 - Anticorps anti-protéine d'interleukine-18 à sensibilité de détection élevée et application associée - Google Patents

Anticorps anti-protéine d'interleukine-18 à sensibilité de détection élevée et application associée Download PDF

Info

Publication number
WO2019194217A1
WO2019194217A1 PCT/JP2019/014748 JP2019014748W WO2019194217A1 WO 2019194217 A1 WO2019194217 A1 WO 2019194217A1 JP 2019014748 W JP2019014748 W JP 2019014748W WO 2019194217 A1 WO2019194217 A1 WO 2019194217A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
seq
monoclonal antibody
amino acid
acid sequence
Prior art date
Application number
PCT/JP2019/014748
Other languages
English (en)
Japanese (ja)
Inventor
浦野　健
裕子 成相
栄治 尾林
宏樹 加美野
Original Assignee
株式会社ｍＡｂＰｒｏｔｅｉｎ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社ｍＡｂＰｒｏｔｅｉｎ filed Critical 株式会社ｍＡｂＰｒｏｔｅｉｎ
Priority to JP2020512280A priority Critical patent/JPWO2019194217A1/ja
Publication of WO2019194217A1 publication Critical patent/WO2019194217A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Definitions

  • the present invention relates to an antibody against interleukin-18 (interleukin-18, hereinafter referred to as IL-18) protein, which is an inflammatory cytokine, and its application.
  • IL-18 interleukin-18
  • IL-18 is a cytokine of the IL-1 ⁇ family and is mainly expressed in macrophages, but is expressed in various cells such as dendritic cells, epithelial cells, keratinocytes.
  • IL-18 receptor is expressed in various cells such as B cells, neutrophils, macrophages, vascular endothelial cells and smooth muscle cells in addition to NK cells, NKT cells, and CD4 T cells.
  • the diversity of IL-18-expressing cells and receptor-expressing cells indicates the diversity of IL-18 functions and is known to be involved in various immune systems.
  • IL-18 has been shown to play an important role in defense mechanisms against pathogens such as parasites and bacterial infections at the time of discovery, but it also plays an important role in allergic diseases and autoimmune diseases. Is shown (Non-Patent Documents 1 and 2).
  • IL-18 unlike cytokines such as TNF, does not undergo production regulation at the mRNA level, and is abundant in cells as an inactive precursor (pro-IL-18). Pro-IL-18 becomes active and is released from the cell by cleaving the precursor with caspase-1 or caspase-4. Therefore, measurement of mRNA expression level and intracellular precursor protein does not measure IL-18 activity, but cleaved by caspase for functional analysis of IL-18. It is essential to analyze the activated IL-18 produced.
  • Patent Documents 1 to 10 Since IL-18 plays an important role in various diseases, many neutralizing antibodies that bind to IL-18 have been reported (Patent Documents 1 to 10). However, since all of these documents are neutralizing antibodies developed for the purpose of treating various diseases involving IL-18, the function as neutralizing activity is disclosed.
  • Non-patent Document 3 Although there is a report that Western blotting was performed using a commercially available polyclonal antibody and active IL-18 was detected (Non-patent Document 3), the detection sensitivity is low, and since it is a polyclonal antibody, The antibody of the same property cannot be stably obtained, and this antibody has already been discontinued. Since IL-18 is present in clinical specimens at a very low concentration, there is an antibody that can perform western blotting with high sensitivity despite the fact that detection is required with high sensitivity. Not.
  • An object of the present invention is to provide an antibody having high specificity for IL-18 and capable of performing Western blotting, immunoprecipitation, and immunostaining, which are important for analyzing the function of IL-18. . It is another object of the present invention to provide an antibody that inhibits the function of IL-18 and can be used not only as a research reagent but also for treatment.
  • the present invention includes the following monoclonal antibodies, functional fragments of monoclonal antibodies, kits containing these antibodies, genes encoding these antibodies or functional fragments, and humanized antibodies, pharmaceutical compositions, test methods, and therapeutic methods About.
  • the heavy chain variable domain consists of the amino acid sequence of GYAFTKYY (SEQ ID NO: 23) or GYTFTDYY (SEQ ID NO: 36), CDR1H region, INPNNGGT (SEQ ID NO: 24), or INPKNGGS (SEQ ID NO: 37).
  • the anti-IL-18 monoclonal antibody according to (1) comprising a CDR3L region consisting of the CDR2L region and the amino acid sequence of VQGTHFYPYT (SEQ ID NO: 28).
  • the amino acid sequence of the heavy chain variable region is any one of SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16, and the amino acid sequence of the L chain variable region is SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22.
  • the anti-IL-18 monoclonal antibody according to (1) or (2) which is any one of them.
  • a kit for detecting and / or quantifying IL-18 which comprises the monoclonal antibody according to any one of (1) to (3) or the functional fragment of the monoclonal antibody according to (5).
  • An anti-IL-18 humanized antibody comprising the CDR of (2) or the variable region of (3) and a human constant region.
  • a pharmaceutical composition used for the treatment of an IL-18-related disease comprising as an active ingredient the monoclonal antibody according to any one of (1) to (3) or the functional fragment of the monoclonal antibody according to (5).
  • the antibodies described in this specification can detect IL-18 with higher sensitivity than currently used antibodies.
  • it is a highly sensitive monoclonal antibody capable of performing Western blotting, it is possible to distinguish and detect active IL-18 and precursor pro-IL-18.
  • it since it also has IL-18 function inhibitory activity, it can also be used for treatment.
  • the figure which shows the specificity of monoclonal antibody 11-4.1 The figure which shows the sensitivity of the monoclonal antibody 11-4.1.
  • FIG. 7A is a diagram showing immunostaining by expressing activated IL-18 with a G196 tag added to HeLa cells.
  • FIG. 7B shows the detection of endogenous IL-18 in HeLa cells by Western blotting and immunostaining.
  • 9A shows the analysis result of 11-4.1
  • FIG. 9B shows the analysis result of 4-18.1.4 and 9-4.2.1.
  • the antibody of the present invention refers to a monoclonal antibody or derivative that specifically binds to the epitope of IL-18 shown below. It also includes functional fragments of the antibody that exhibit substantially the same antigen specificity as the original antibody. Functional fragments of antibodies include functional fragments of antibodies such as Fab, Fab ′, F (ab ′) 2 , single chain antibodies (scFv), disulfide stabilized V region fragments (dsFv), or peptides containing CDRs. included.
  • humanized antibodies and genetically modified mice in which monoclonal antibodies that specifically bind to the epitope of IL-18 identified in the present invention are transformed into human-type chimeric antibodies, humanized CDR-grafted antibodies, etc. using gene recombination technology,
  • the human antibody used is also included in the antibody of the present invention.
  • humanized antibodies and human antibodies When administered to humans, have fewer side effects than non-human animal antibodies, and their therapeutic effects last for a long time.
  • Epitope refers to a part of an antigen (IL-18 in the present invention) recognized by an antibody, and refers to a site on an antigen to which a domain containing an antibody variable region disclosed herein binds. means.
  • an antibody may recognize a linear amino acid sequence or a three-dimensional structure. And can be defined by the structure of the antigen.
  • IL-18-related disease refers to a disease caused by excessive release of active IL-18 to the outside of a cell or a disease that may be exacerbated by IL-18. Since an IL-18-related disease is a disease that develops and exacerbates due to overexpression of IL-18, it can be treated or prevented with a drug containing an active ingredient that can inhibit the function of IL-18. it can.
  • AOSD adult Still disease
  • SLE systemic lupus erythematosus
  • JIA juvenile idiopathic Arthritis
  • CDPD chronic obstructive pulmonary disease
  • BPD bronchopulmonary dysplasia
  • ARDS acute respiratory distress syndrome
  • Idiopathic pulmonary fibrosis cystic fibrosis
  • rheumatoid arthritis metabolic bone disease, severe organ injury in the liver and intestine, heart failure, amyotrophic lateral sclerosis (ALS), xerophthalmia (DED) ), Keratitis, corneal neovascularization, pathological intraocular neovascularization, ulceris, glaucoma, macular de
  • kit is not limited to Western blotting, immunoprecipitation, immunostaining, and IL-18 function inhibition activity test shown in the following Examples, but also includes the use of the antibody disclosed herein and IL-18.
  • a packaged combination including necessary reagents and instruments as constituent elements.
  • the test means detection of active IL-18 for the purpose of determining whether or not active IL-18 is present in a sample. Specifically, it refers to detecting whether active IL-18 is present in a sample using a patient sample.
  • samples such as plasma, serum, blood, spinal fluid, urine can be used.
  • the pharmaceutical composition is formulated so as to be compatible with the administration route.
  • the administration route can be formulated into a dosage form suitable for a disease such as ointment, ophthalmic preparation and the like, as well as parenteral administration such as intravenous administration, subcutaneous administration and intravitreal administration.
  • the pharmaceutical composition can include compounds that can be generally used in the art, such as carriers, excipients, solvents, diluents, and the like suitable for the dosage form.
  • Example 1 Production of antibody pET28HisTEV (non-patent document) encodes a gene region encoding a polypeptide (active IL-18, SEQ ID NO: 1) at positions 37 to 193 of human inflammatory cytokine IL-18 protein (uniprot: Q14116) It was cloned into literature 4), expressed in E. coli and purified. The purified protein was immunized to mice according to a conventional method, and the purified protein used for the antigen was selected by ELISA to establish a hybridoma.
  • 11-4.1 antibody three monoclonal antibodies that recognize the same epitope 11-4.1 monoclonal antibody (hereinafter referred to as 11-4.1 antibody; other antibodies are also described in the same manner), 4-18
  • the hybridomas 11-4.1, 4-18.1.4, and 9-4.2.1 that produce the .1.4 antibody and the 9-4.2.1 antibody were selected and analyzed.
  • the application of Western blotting, immunostaining, etc. will be described mainly for the 11-4.1 antibody.
  • the other two monoclonal antibodies have the same epitope, such as Western blotting etc. It can be used for the analysis of the same technique.
  • Example 2 Evaluation of specificity of monoclonal antibody 11-4.1 produced by hybridoma 11-4.1 G196 tag (aspartic acid-leucine-valine-proline-arginine, DLVPR, hereinafter, amino acid sequence is expressed in one letter
  • the human inflammatory cytokine IL-1 ⁇ family protein fused with SEQ ID NO: 2) was expressed in human fetal kidney-derived cell line HEK-293 cells. The expressed protein was evaluated for 11-4.1 antibody using Western blotting (FIG. 1).
  • the 11-4.1 antibody recognizes only the IL-18 protein, and the IL-1 ⁇ family of IL-1 ⁇ , ⁇ , Ra (Receptor antagonist), IL-33, IL-36 ⁇ , ⁇ 1, ⁇ 2, ⁇ , Ra IL-37 and IL-38 isoforms IL-38-1 and IL-38-2 did not react. Since it did not bind to other proteins of the IL-1 ⁇ family, it can be said to be a highly specific antibody.
  • the G196 tag is a tag sequence detected by the G196 monoclonal antibody (Patent Document 11). The Western blotting with the G196 monoclonal antibody shown in the lower part is for showing that each protein is expressed.
  • each primary antibody is used at a concentration of 3.2 ⁇ g / mL for 1: 125 fold dilution and 16 ⁇ g / mL for 1:25 fold dilution. All other conditions such as exposure time and secondary antibody were the same (FIG. 2).
  • the 11-4.1 antibody was able to detect a protein having a concentration of 3.3 ng / mL at 1:25 dilution. In contrast, at the same dilution ratio, the D043-3 antibody was able to detect a protein at a concentration of 100 ng / mL, and the M156-3 antibody was not detectable at any concentration. The 11-4.1 antibody was found to be about 60 times more sensitive than D043-3, which was confirmed to be detected.
  • Example 4 Evaluation using clinical specimen (1) Evaluation using 11-4.1 antibody using clinical specimen
  • IL-18 is produced at the mRNA level unlike cytokines such as TNF. Unregulated and abundant in cells as inactive precursors. Therefore, measurement of mRNA expression level and intracellular precursor protein does not reflect the activity of IL-18, and in order to analyze the function of IL-18, active IL-18, ie, cleaved It is essential to detect IL-18 protein.
  • the 11-4.1 antibody is much more sensitive than the commercially available anti-IL-18 antibody, is it possible to detect active IL-18 in clinical specimens? investigated. The following research has been approved by the Ethics Committee of Shimane University School of Medicine.
  • IL-18 protein in the serum of adult-onset Still's disease (AOSD) patients reported to have high IL-18 protein was detected by capillary western immunoassay using Wes.
  • the 11-4.1 antibody was adjusted to 0.4 mg / mL and then used at a 1: 125 dilution (3.2 ⁇ g / mL).
  • the 11-4.1 antibody can detect active IL-18 in the serum of AOSD patients.
  • the 11-4.1 antibody is a highly sensitive and useful antibody.
  • the bar shown below the sample number indicates that the sample is from the same patient, but not only can a small amount of active IL-18 contained in the serum be detected, but also samples 53 and 54 (FIG. 3).
  • the 11-4.1 antibody can be used as a diagnostic agent for IL-18-related diseases. It should be noted that no patient information is obtained for the sample 52 other than that it is an AOSD case.
  • IL-18 protein in the sera of patients with hemophagocytic syndrome was detected by capillary western immunoassay using Wes as described above.
  • 11-4.1 was adjusted to 0.4 mg / mL and then used at a 1: 125 dilution.
  • active IL-18 protein cleaved with active caspase 4 105-377 was used at concentrations of 40, 20, 10, 5, and 2.5 ng / mL. The results are shown in FIG. In 2 of 6 patients (# 2, # 5), protein was detected at the same position as active IL-18, ie, active IL-18 cleaved by caspase.
  • ELISA can detect IL-18 with enhanced sensitivity, but since there is no antibody that can specifically recognize active IL-18, only active IL-18 cannot be directly detected by ELISA. It is clinically meaningful that active IL-18 can be detected in the serum of patients with AOSD or hemophagocytic syndrome by confirming the molecular weight by capillary western immunoassay.
  • Example 5 Immunoprecipitation method with 11-4.1 antibody IL-18 37-193 -G196 / a vector that is expressed by fusing a G196 tag to an active IL-18 polypeptide at positions 37 to 193
  • the pcDNA3 vector was introduced into HEK-293 cells to express the IL-18 37-193- G196 protein.
  • the usefulness of the 11-4.1 antibody in the immunoprecipitation method was evaluated in comparison with the existing G196 tag antibody (FIG. 5).
  • 11-4.1 antibody, G196 antibody, Flag tag antibody (M2, Sigma-Aldrich) was used as a negative control antibody, immunoprecipitation was performed, and immunoprecipitation products were detected by Western blotting with G196 rabbit polyclonal antibody.
  • the 11-4.1 antibody immunoprecipitated IL-18 37-193 -G196 protein expressed in HEK-293 cells in the same manner as the existing G196 antibody. That is, it was revealed that the 11-4.1 antibody is a monoclonal antibody that can specifically recognize IL-18 protein and efficiently immunoprecipitate.
  • IL-18 function inhibitory activity by 11-4.1 antibody When active IL-18 protein expressed and purified in E. coli is added to acute myeloid leukemia cell line KG-1 (JCRB0065), IFN- ⁇ is produced. It is known that If the 11-4.1 antibody is an antibody that inhibits IL-18 function, IFN- ⁇ production by IL-18 is inhibited.
  • a gene region encoding a polypeptide at positions 2 to 193 of the IL-18 protein was cloned into pET28HisTEV, expressed in E. coli and purified.
  • the gene region encoding the polypeptide at positions 105 to 377 of human caspase 4 protein was cloned into pET28HisTEV, expressed in E. coli and purified. These two proteins were mixed to purify the active IL-18 protein (SEQ ID NO: 1).
  • Activated IL-18 purified by the above method at 2 ng / well and antibody at a concentration of 0 to 2.0 ⁇ g were added to 3 ⁇ 10 4 cells / 96 well KG-1 cells, and 36 hours later, IFN in the culture supernatant - ⁇ was measured using an IFN- ⁇ detection ELISA kit (Diacron).
  • the function of IL-18 is inhibited in a concentration-dependent manner by adding the 11-4.1 antibody to the culture solution simultaneously with the active IL-18 protein. That is, the 11-4.1 antibody acts as a neutralizing antibody that inhibits the function of IL-18.
  • IC 50 is 14.2 nM, and has an activity to inhibit the function of IL-18 at a very low concentration. Therefore, the antibody of the present invention can be used as a therapeutic agent for IL-18-related diseases.
  • Example 7 Immunostaining with 11-4.1 antibody IL-18 37-193 -G196 / pcDNA3 vector was introduced into HeLa cells to express IL-18 37-193 -G196 protein. After formalin fixation, immunostaining was performed using 11-4.1 antibody as a primary antibody and Alexa488-labeled anti-mouse antibody (A-11029, Thermo Fisher Scientific) as a secondary antibody according to a conventional method. As shown in FIG. 7 (A), the 11-4.1 antibody strongly recognized IL-18 37-193 -G196 protein transiently expressed in HeLa cells in the cytoplasm. In addition, as control, what reacted only the secondary antibody is shown.
  • FIG. 7B shows that endogenous IL-18 protein was expressed in HeLa cells.
  • the endogenous IL-18 protein in HeLa cells is analyzed by Western blotting, full-length IL-18 that is not cleaved by caspase is detected as the main molecular species (FIG. 7 (B) left).
  • IL-18 protein was detected in the whole cell including the nucleus of HeLa cells.
  • the 11-4.1 antibody can detect endogenous IL-18 protein expressed in HeLa cells by Western blotting or immunostaining.
  • the immunostained image in FIG. 7B is obtained by further black-and-white reversal of the image that has been converted to grayscale after imaging.
  • the antibody of the present invention was analyzed by Western blotting and immunostaining using the same antibody. I can make my presence clear. Since conventional antibodies could not perform Western blotting with high sensitivity, even if the localization in the cells was clarified, it was not possible to distinguish the molecular species of full length and active type. On the other hand, since the antibody of the present invention can be applied to various methods, multifaceted analysis can be performed.
  • Example 8 Epitope analysis A plasmid was prepared by pGEX-4T-2 (GE Healthcare Japan) to express active IL-18 as a GST fusion protein 15 amino acids from the N terminus. Each plasmid was expressed in E. coli, and the sequence recognized by the 11-4.1 antibody was analyzed by Western blotting using the 11-4.1 antibody. The secondary antibody was detected with ImageQuantLAS 4000 (GE Healthcare) using a peroxidase-labeled anti-mouse antibody (710-1332, Rockland). As shown in FIG. 8 (A), the 11-4.1 antibody showed strong reactivity with the 58th to 72nd amino acids.
  • FIG. 8B Western blotting
  • a plasmid was constructed with pGEX-4T-2 to express the amino acid sequence of GST as a GST fusion protein.
  • the antibody 11-4.1 recognizes a GST fusion protein containing the amino acid sequence from positions 62 to 70, but did not recognize the amino acid sequence from positions 64 to 72 (FIG. 8 (B) right).
  • the 11-4.1 antibody is recognized by mutating the amino acid in the region from asparagine at position 62 to threonine at position 70 (NRPLFEDMT) of IL-18 protein expressed as a GST fusion protein in E. coli to alanine. The analysis was done. Western blotting was performed using 11-4.1 antibody and quantified with ImageQuantLAS 4000.
  • the antibody 11-4.1 is a mutant in which arginine at position 63 is changed to alanine (hereinafter referred to as R63A mutant.
  • the mutant (D68A) in which the aspartic acid at position 68 was changed to alanine was hardly recognized.
  • the L65A mutant, F66A mutant, and E67A mutant showed only about half recognition of the wild type (lane left end).
  • the 11-4.1 antibody showed the same recognition as the wild-type peptide for the N62A mutant, P64A mutant, M69A mutant, and T70A mutant.
  • the 11-4.1 antibody is sterically structured and has arginine (R) and 68 at position 63 exposed on the surface. It is considered that leucine-phenylalanine-glutamic acid (LFE) from the 65th position to the 67th position is recognized centering on the aspartic acid (D) at the position.
  • LFE leucine-phenylalanine-glutamic acid
  • the recognition sites were also analyzed for the other two monoclonal antibodies obtained in Example 1, the 4-18.1.4 antibody and the 9-4.2.1 antibody (FIG. 9 (B)).
  • 4-18.1.4 antibody and 9-4.2.1 antibody like 11-4.1 antibody, hardly recognize R63A mutant and D68A mutant, and L65A mutant, F66A mutant, Only about half of the wild type E67A mutant could be recognized.
  • the M69A mutant and the T70A mutant were recognized in the same manner as the wild type. Therefore, it is considered that the epitopes of the three types of antibodies, the 11-4.1 antibody, the 4-18.1.4 antibody, and the 9-4.2.1 antibody, are the same. That is, these three monoclonal antibodies are antibodies that recognize RXLFED (SEQ ID NO: 5) as an epitope.
  • the established hybridoma was confirmed for its isotype using an IsoStripe TM mouse monoclonal antibody isotyping kit (manufactured by Sigma-Aldrich).
  • the isotypes of the 11-4.1 antibody, the 4-18.1.4 antibody, and the 9-4.2.1 antibody were all IgG2b and ⁇ .
  • the 4-18.1.4 antibody and the 9-4.2.1 antibody have the same epitope as the 11-4.1 antibody, and, like the 11-4.1 antibody, western blotting, immunoprecipitation, immunization It can be used by various methods such as dyeing and ELISA. Moreover, it has IL-18 function inhibitory activity, such as the 11-4.1 antibody, and can be applied in clinical aspects such as treatment of diseases caused by overexpression of IL-18.
  • Example 9 Affinity analysis with epitope peptide Since the epitope is clarified and the affinity of the obtained monoclonal antibody is considered to be very high, the affinity was measured by surface plasmon resonance analysis. It was.
  • a peptide QGNLPLFEDMTDSGSGSC, SEQ ID NO: 6) having a linker sequence GSGS and a cross-linking Cys added to the C-terminus as a spacer to the 60- to 72-position sequence containing the epitope of IL-18 protein as a sensor chip CM5 by the ligand thiol coupling method (GE Healthcare, BR100012) was immobilized and analyzed.
  • the purified antibody 11-4.1 was measured by single-cycle using Biacore X100 (GE Healthcare) in a 5-fold, 5-fold dilution series in the range of 0.08 nM to 50 nM (FIG. 10). Analysis was performed using bivalent analysis. The actually measured values and the conformity analysis data are almost the same, and K D : 1.25 ⁇ 10 ⁇ 11 M, K a : 3.3 ⁇ 10 6 M ⁇ 1 S ⁇ 1, K d : 4.1 ⁇ 10 ⁇ 5 s ⁇ 1 It was. It was confirmed experimentally that the affinity was very high.
  • the sequence of the antibody gene in the hypervariable region and the amino acid sequence of the synthesized cDNA were determined by a direct sequencing method using H and L chain primer sets.
  • H chain primer VH1-1S 5'-ggggatcc ag gts mar ctg cag sag tcw gg-3 '(SEQ ID NO: 7)
  • the base sequence of the 11-4.1 antibody SEQ ID NO: 11
  • the amino acid sequence SEQ ID NO: 12
  • the base sequence of the 4-18.1.4 antibody SEQ ID NO: 13
  • the amino acid sequence SEQ ID NO: 14
  • 9-4.2.1 The nucleotide sequence (SEQ ID NO: 15) and amino acid sequence (SEQ ID NO: 16) of the antibody were determined.
  • the base sequence of the 11-4.1 antibody (SEQ ID NO: 17), the amino acid sequence (SEQ ID NO: 18), the base sequence of the 4-18.1.4 antibody (SEQ ID NO: 19), the amino acid The sequence (SEQ ID NO: 20), the base sequence of the 9-4.2.1 antibody (SEQ ID NO: 21), and the amino acid sequence (SEQ ID NO: 22) were determined.
  • CDR complementarity determining region
  • hybridomas 11-4.1 and 4-18.1.4 were completely identical.
  • amino acid sequences of the heavy chain and light chain variable regions of 11-4.1 and 4-18.1.4 differed only in one place, and the other regions were identical as far as they were compared.
  • Hybridomas 11-4.1 and 9-4.2.1 had some differences in the amino acid sequences of CDR1 and CDR2 of the heavy chain, but all other CDRs were identical.
  • any antibody having these CDRs binds to the same epitope and exhibits similar properties.
  • the antibody disclosed in the present specification can be used not only for various experiments such as Western blotting, immunoprecipitation, immunostaining, but also inhibit the function of IL-18. It is a very useful antibody.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)

Abstract

La présente invention concerne un anticorps monoclonal produit par un hybridome établi qui exprime une sélectivité élevée pour l'IL-18, et qui est également capable d'effectuer un transfert de western, une immunoprécipitation et une immunocoloration qui sont importantes pour l'analyse des fonctions de l'IL-181. En particulier, l'anticorps peut effectuer un transfert de western avec une sensibilité élevée, et peut ainsi détecter l'IL-18 active. De plus, l'anticorps inhibe les fonctions de l'IL-18, et peut ainsi également être utilisé à des fins de traitement.
PCT/JP2019/014748 2018-04-04 2019-04-03 Anticorps anti-protéine d'interleukine-18 à sensibilité de détection élevée et application associée WO2019194217A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020512280A JPWO2019194217A1 (ja) 2018-04-04 2019-04-03 検出感度の高いインターロイキン−１８タンパク質に対する抗体及びその応用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2018072006 2018-04-04
JP2018-072006 2018-04-04
JP2018-246840 2018-12-28
JP2018246840 2018-12-28

Publications (1)

Publication Number Publication Date
WO2019194217A1 true WO2019194217A1 (fr) 2019-10-10

Family

ID=68100289

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/014748 WO2019194217A1 (fr) 2018-04-04 2019-04-03 Anticorps anti-protéine d'interleukine-18 à sensibilité de détection élevée et application associée

Country Status (2)

Country Link
JP (1) JPWO2019194217A1 (fr)
WO (1) WO2019194217A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012139224A (ja) * 2000-02-10 2012-07-26 Abbott Lab ヒトインターロイキン１８に結合する抗体とその調整方法および使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012139224A (ja) * 2000-02-10 2012-07-26 Abbott Lab ヒトインターロイキン１８に結合する抗体とその調整方法および使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FURUYA, DAISUKE ET AL.: "An immuno-polymerase chain reaction assay for human interleukin-18", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 238, no. 1-2, April 2000 (2000-04-01), pages 173 - 180, XP004195473, DOI: 10.1016/S0022-1759(00)00143-5 *
MORIWAKI, YUJI ET AL.: "Elevated Levels of Interleukin-18 and Tumor Necrosis Factor-a in Serum of Patients With Type2 Diabetes Mellitus : Relationship With Diabetic Nephropathy", METABOLISM, vol. 52, no. 5, May 2003 (2003-05-01), pages 605 - 608, XP055643064 *

Also Published As

Publication number Publication date
JPWO2019194217A1 (ja) 2021-04-15

Similar Documents

Publication Publication Date Title
JP6548696B2 (ja) ヒト抗ｉｌ−３３中和モノクローナル抗体
RU2753512C2 (ru) Антитело против злокачественной клетки, противораковое лекарственное средство и способ тестирования злокачественного новообразования
AU2012320597B2 (en) oxMIF as a diagnostic marker
JP2019055957A (ja) Ａｐｒｉｌ結合ペプチドを得るための方法、そのペプチドを生成するためのプロセス、前記方法／プロセスを用いて入手可能なａｐｒｉｌ結合ペプチドおよびａｐｒｉｌ結合ペプチドの使用
JP2015508763A (ja) ペプチドグリカン認識タンパク質１に結合する抗体
CN113330036A (zh) 结合pd-l1和ox40的双特异性抗体
EP3533459A1 (fr) Anticorps anti-pla2-gib et leurs utilisations
JP6501650B2 (ja) ヒト抗ｉｌ−３３中和モノクローナル抗体
JP6892180B2 (ja) 活性型インターロイキン−１８タンパク質のネオエピトープを認識する抗体、及びその応用
TW201734051A (zh) 抗ｔｍｅｍ－１８０抗體、抗癌劑、及癌之檢查方法
US20190040119A1 (en) Method for producing antibody
AU2016293807A1 (en) Antibody which specifically binds to human CRTH2
WO2022093641A1 (fr) Agents anti-nkg2a et compositions et méthodes de production et d'utilisation de ceux-ci
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
US20220251228A1 (en) Anti-bcma antibody, antigen-binding fragment thereof and medical use thereof
JP7197865B2 (ja) 抗ヒトｃｃｒ１モノクローナル抗体
TWI782000B (zh) 抗ｇｐｒ２０抗體、其製造方法及其應用
WO2019194217A1 (fr) Anticorps anti-protéine d'interleukine-18 à sensibilité de détection élevée et application associée
EP4293360A1 (fr) Méthode d'inspection de la maladie de still chez un adulte et kit d'inspection
CN117242092A (zh) Vegfa结合分子
CN110878122B (zh) 重组抗pd-l1单克隆抗体
CN112979798B (zh) 一种包含c反应蛋白抗原结合结构域的分离的结合蛋白
CN112724251B (zh) 一种包含c反应蛋白抗原结合结构域的结合蛋白
JP2024156980A (ja) ヒト抗ｉｌ－３３中和モノクローナル抗体
WO2009116491A1 (fr) Anticorps monoclonal reconnaissant spécifiquement le sous-type alpha 8 de l'interféron alpha humain et protéine mutante associée

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2020512280

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19781860

Country of ref document: EP

Kind code of ref document: A1